<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05093582</url>
  </required_header>
  <id_info>
    <org_study_id>H20082689</org_study_id>
    <nct_id>NCT05093582</nct_id>
  </id_info>
  <brief_title>The Effects of Levcromakalim in Patients With Cluster Headache</brief_title>
  <official_title>The Headache-inducing Effects of Levcromakalim in Patients With Cluster Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cluster headache is a primary headache disorder characterized by attacks of unilateral&#xD;
      headache of short duration and severe pain intensity. There is an unmet need to understand&#xD;
      the underlying disease mechanisms that will ultimately lead to the development of&#xD;
      disease-specific medicines. Until now, it has been suggested that the calcitonin gene-related&#xD;
      peptide (CGRP) plays a major role in the initiation of a cluster headache attack, possibly&#xD;
      involving the ATP-sensitive potassium channels. The current study aims to determine whether&#xD;
      the opening of ATP-sensitive potassium channels triggers cluster headache attacks in patients&#xD;
      with cluster headache.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of cluster headache attacks</measure>
    <time_frame>Change from baseline at 90 minutes after drug administration</time_frame>
    <description>Experimentally induced cluster headache attacks must fulfill either:&#xD;
Headache described as mimicking the patient's usual cluster headache attack (with or without cephalic autonomic symptom).&#xD;
Headache fulfilling criteria A and B for cluster headache according to International Classification of Headache Disorders criteria:&#xD;
A. Severe unilateral pain lasting 15 to 180 minutes.&#xD;
B. Either or both of the following:&#xD;
At least 1 cephalic autonomic symptom ipsilateral to the headache.&#xD;
A sense of restlessness or agitation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of headache</measure>
    <time_frame>Change from baseline at 90 minutes after drug administration</time_frame>
    <description>Yes/no questions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of headache intensity scores</measure>
    <time_frame>Change from baseline at 90 minutes after drug administration</time_frame>
    <description>Headache intensity scores are measured by a numerical rating scale (NRS). It is a verbally declared scale from 0 to 10, where 0 is no headache; 1 is a very mild headache, including a feeling of pressing or throbbing; 5 is a moderate headache; 10 is the worst imaginable headache.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Cluster Headache</condition>
  <arm_group>
    <arm_group_label>Levcromakalim</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous infusion of levcromakalim (1 mg/20 ml). The infusion is administered at constant speed by an automatic pump, lasting 20 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous infusion of placebo (sterile saline, 20 ml). The infusion is administered at constant speed by an automatic pump, lasting 20 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levcromakalim</intervention_name>
    <description>12 active episodic patients, 15 episodic patients in remission and 20 chronic patients of both genders are randomized to receive a 20-minute infusion of levcromakalim and/or sterile saline on two days, with at least one week in between.</description>
    <arm_group_label>Levcromakalim</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>12 active episodic patients, 15 episodic patients in remission and 20 chronic patients of both genders are randomized to receive a 20-minute infusion of levcromakalim and/or sterile saline on two days, with at least one week in between.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Isotonic saline</other_name>
    <other_name>0.9% saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cluster headache patients meeting ICHD-3 criteria for episodic and chronic cluster&#xD;
             headache of either sex. Patients were defined as having episodic cluster headache in&#xD;
             the active phase when they had usual attacks within the last 30 days, episodic cluster&#xD;
             headache in the remission phase when they were attack-free for at least 30 days, or&#xD;
             chronic cluster headache when they had not had more than 30 consecutively attack-free&#xD;
             days over the last 12 months or longer.&#xD;
&#xD;
          -  Weight between 50 and 100 kg.&#xD;
&#xD;
          -  All preventive medications, except steroid treatments or greater occipital nerve&#xD;
             blockade within 30 days, were allowed with stable dosing.&#xD;
&#xD;
          -  Negative urinary HCG at baseline.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary headache types except above.&#xD;
&#xD;
          -  Secondary headache disorders, according to ICHD-3.&#xD;
&#xD;
          -  Headache at baseline.&#xD;
&#xD;
          -  Anamnestic information or clinical signs of (at inclusion date) hypertension (systolic&#xD;
             blood pressure &gt;150 mmHg and/or diastolic blood pressure &gt;100 mmHg) or hypotension&#xD;
             (systolic blood pressure &lt; 90 mmHg and/or diastolic blood pressure &lt; 50 mmHg)&#xD;
&#xD;
          -  Known severe or treatment-requiring cardiovascular disease including cerebrovascular&#xD;
             disease.&#xD;
&#xD;
          -  Anamnestic or clinical evidence of mental disorder or substance abuse.&#xD;
&#xD;
          -  Anamnestic or clinical evidence of any disease considered by the investigating&#xD;
             physician to be relevant to participation in the study.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Messoud Ashina, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danish Headache Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Messoud Ashina, MD, PhD</last_name>
    <phone>+4526252395</phone>
    <email>ashina@dadlnet.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lanfranco Pellesi, MD</last_name>
    <email>lanfranco.pellesi@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Danish Headache Center</name>
      <address>
        <city>Glostrup</city>
        <state>Copenhagen</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rigmor H Jensen, MD</last_name>
      <email>rigmor.jensen@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 17, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Headache Center</investigator_affiliation>
    <investigator_full_name>Messoud Ashina</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cluster Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cromakalim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

